Short-term direct oral anticoagulant therapy following successful transcatheter aortic valve replacement substantially reduces hypoattenuated leaflet thickening during treatment compared with single antiplatelet therapy alone, according to findings from the NOTION-4 trial presented at the ESC Congress and simultaneously published in JACC. However, researchers noted that this protective effect diminishes roughly nine months after discontinuing the anticoagulant regimen, raising clinical questions about the long-term management of structural heart patients.
NOTION-4 Trial Design and Patient Randomization
Investigators in the NOTION-4 trial randomized 352 patients without an existing indication for oral anticoagulation shortly after undergoing successful transcatheter aortic valve replacement, commonly known as TAVR. Patients received either lifelong single antiplatelet therapy or a three-month course of direct oral anticoagulant therapy followed by lifelong single antiplatelet therapy, according to the trial protocol. The primary endpoint measured by the research team was the prevalence of hypoattenuated leaflet thickening, or HALT, at 12 months using serial cardiac computed tomography scans.
At the three-month mark, researchers observed hypoattenuated leaflet thickening in approximately 32% of patients assigned to the single antiplatelet therapy group, compared to just 12% of patients treated with the direct oral anticoagulant regimen. Cardiac surgery specialists and invasive cardiologists often track these imaging changes to understand valve prosthesis durability and thrombosis risks. Yet, by the one-year mark, the gap in leaflet thickening between the two cohorts narrowed significantly among patients with available follow-up scans, showing 32% prevalence in the single antiplatelet group versus 28% in the short-term direct oral anticoagulant group.
Did you know? Hypoattenuated leaflet thickening (HALT) is an imaging finding detected on cardiac CT scans that shows reduced motion or thickening of prosthetic heart valve leaflets, often managed with tailored antithrombotic therapy regimens.
Clinical Outcomes and Bleeding Risks at One Year
Beyond imaging endpoints, the trial tracked hard clinical outcomes including all-cause mortality, stroke, and major or life-threatening bleeding events at 12 months. According to the published data, the combined rate of these clinical events reached 2.3% in the single antiplatelet therapy group, compared to 8.2% in the cohort that received short-term direct oral anticoagulant therapy. This higher numerical incidence of clinical events, driven largely by bleeding complications, weighs heavily on safety assessments.
“Although the trial’s precisions at 12 months do not allow us to confirm or rule out a modest, sustained effect on HALT in the [DOAC] group, the serial cardiac CT scans suggest that the impact of short-term DOAC therapy on HALT is not permanent,” write Troels Højsgaard Jørgensen, MD, PhD, et al., in their published findings. The authors added that because the short-term reduction in leaflet thickening did not translate into a clinical benefit, the data reinforce established clinical standards. These findings support current guidelines that recommend against the routine use of direct oral anticoagulants after transcatheter aortic valve replacement in patients who lack another independent clinical indication for oral anticoagulation.
Pro Tip: When evaluating post-procedural antithrombotic protocols for structural heart interventions, clinicians should balance subclinical imaging findings against patient-specific bleeding risks and established professional society guidelines. Read more cardiology updates on our Cardiology News Hub.
Frequently Asked Questions
What is hypoattenuated leaflet thickening (HALT) after TAVR?
Hypoattenuated leaflet thickening is an imaging phenomenon observed on cardiac CT scans where prosthetic valve leaflets appear thickened and show reduced motion, indicating potential subclinical thrombus formation.
Did the short-term DOAC regimen prevent HALT permanently?
No. While three months of direct oral anticoagulant therapy substantially reduced leaflet thickening during treatment, researchers found that the protective effect diminished approximately nine months after discontinuing the therapy.
Do current guidelines recommend routine DOAC use after TAVR?
Current guidelines recommend against the routine use of direct oral anticoagulants after transcatheter aortic valve replacement in patients without another clinical indication for oral anticoagulation, due to a lack of proven clinical benefit and an increased risk of bleeding.
Want to stay updated on the latest clinical trials and ESC Congress presentations? Subscribe to our weekly medical briefing or leave a comment below with your thoughts on post-TAVR antithrombotic management.
Worth a look